Par Drugs and Chemicals Gestion

Gestion contrôle des critères 3/4

Le PDG Par Drugs and Chemicals est Jignesh Savani, nommé en Nov2018, a un mandat de 25.75 ans. La rémunération annuelle totale est ₹ 5.19M, composée du salaire de 99.3% et des bonus 0.7%, y compris les actions et options de la société. détient directement 42.36% des actions de la société, d'une valeur de ₹ 1.53B. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 6 ans et 6.3 ans.

Informations clés

Jignesh Savani

Directeur général

₹5.2m

Rémunération totale

Pourcentage du salaire du PDG	99.3%
Durée du mandat du directeur général	6yrs
Propriété du PDG	42.4%
Durée moyenne d'occupation des postes de direction	6yrs
Durée moyenne du mandat des membres du conseil d'administration	6.3yrs

Mises à jour récentes de la gestion

Recent updates

There's No Escaping Par Drugs and Chemicals Limited's (NSE:PAR) Muted Earnings Despite A 26% Share Price Rise

Oct 29

Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Apr 16

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Apr 05

Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

Nov 03

If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

May 19

Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Mar 17

Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Oct 22

Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Aug 11

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Jul 14

Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Mar 31

Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Mar 05

Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Feb 06

Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Jan 10

How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

Dec 13

Analyse de la rémunération des PDG

Comment la rémunération de Jignesh Savani a-t-elle évolué par rapport aux bénéfices de Par Drugs and Chemicals?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	₹183m
Jun 30 2024	n/a	n/a	₹146m
Mar 31 2024	₹5m	₹5m	₹145m
Dec 31 2023	n/a	n/a	₹142m
Sep 30 2023	n/a	n/a	₹127m
Jun 30 2023	n/a	n/a	₹115m
Mar 31 2023	₹5m	n/a	₹113m
Dec 31 2022	n/a	n/a	₹103m
Sep 30 2022	n/a	n/a	₹106m
Jun 30 2022	n/a	n/a	₹91m
Mar 31 2022	₹5m	₹5m	₹92m
Dec 31 2021	n/a	n/a	₹112m
Sep 30 2021	n/a	n/a	₹112m
Jun 30 2021	n/a	n/a	₹115m
Mar 31 2021	₹4m	₹4m	₹116m
Dec 31 2020	n/a	n/a	₹88m
Sep 30 2020	n/a	n/a	₹83m
Jun 30 2020	n/a	n/a	₹65m
Mar 31 2020	₹4m	n/a	₹48m

Rémunération vs marché: La rémunération totale de Jignesh ($USD 61.41K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Indian ($USD 42.61K ).

Rémunération et revenus: La rémunération de Jignesh a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Jignesh Savani (47 yo)

6yrs

Titularisation

₹5,185,000

Compensation

Mr. Jignesh Vallabhbhai Savani is Promoter of at Par Drugs and Chemicals Limited and has been its Chief Executive Officer since November 26, 2018 and serves as its Executive Director since February 26, 199...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Falgun Savani	Chairman of the Board & MD	25.8yrs	₹5.21m	21.5% ₹ 778.0m
Jignesh Savani	CEO & Executive Director	6yrs	₹5.19m	42.36% ₹ 1.5b
Chintan Chauhan	Chief Financial Officer	6yrs	₹589.00k	pas de données
Sanket Trivedi	Company Secretary & Compliance Officer	6.2yrs	₹663.00k	pas de données
Ghanshayambhai Savani	Whole Time Director	6yrs	₹5.18m	6.52% ₹ 235.9m

6.0yrs

Durée moyenne de l'emploi

47yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de PAR est chevronnée et expérimentée (6 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Falgun Savani	Chairman of the Board & MD	25.8yrs	₹5.21m	21.5% ₹ 778.0m
Jignesh Savani	CEO & Executive Director	25.8yrs	₹5.19m	42.36% ₹ 1.5b
Ghanshayambhai Savani	Whole Time Director	12.6yrs	₹5.18m	6.52% ₹ 235.9m
Pravin Bhayani	Lead Independent Director	5.8yrs	₹1.29m	pas de données
Kajal Vaghani	Independent Director	5.8yrs	₹40.00k	pas de données
Krishna Shah	Independent Director	5.8yrs	₹90.00k	pas de données
Nayna Savani	Non Executive Director	6.8yrs	₹50.00k	3.08% ₹ 111.4m
Bintal Bhaveshkumar Shah	Independent Director	4.2yrs	₹25.00k	pas de données

6.3yrs

Durée moyenne de l'emploi

47.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de PAR sont considérés comme expérimentés (ancienneté moyenne 6.3 ans).

Par Drugs and Chemicals Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

CEO & Executive Director recently sold ₹23m worth of stock

Par Drugs and Chemicals Limited, Annual General Meeting, Sep 21, 2024

Insufficient new directors

Par Drugs and Chemicals Limited, Annual General Meeting, Sep 16, 2023

Par Drugs and Chemicals Limited, Annual General Meeting, Sep 10, 2022

Non Executive Director recently bought ₹304k worth of stock

Recent updates

Investor sentiment improves as stock rises 35%

There's No Escaping Par Drugs and Chemicals Limited's (NSE:PAR) Muted Earnings Despite A 26% Share Price Rise

Second quarter 2025 earnings released: EPS: ₹6.99 (vs ₹3.97 in 2Q 2024)

CEO & Executive Director recently sold ₹23m worth of stock

Par Drugs and Chemicals Limited, Annual General Meeting, Sep 21, 2024

First quarter 2025 earnings released: EPS: ₹2.06 (vs ₹2.01 in 1Q 2024)

Full year 2024 earnings released: EPS: ₹11.78 (vs ₹9.21 in FY 2023)

Now 23% overvalued after recent price rise

Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Third quarter 2024 earnings released: EPS: ₹2.78 (vs ₹1.52 in 3Q 2023)

Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

Second quarter 2024 earnings released: EPS: ₹3.97 (vs ₹3.03 in 2Q 2023)

Insufficient new directors

Investor sentiment improves as stock rises 15%

Par Drugs and Chemicals Limited, Annual General Meeting, Sep 16, 2023

First quarter 2024 earnings released: EPS: ₹2.01 (vs ₹1.86 in 1Q 2023)

Investor sentiment improves as stock rises 23%

If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

Full year 2023 earnings released: EPS: ₹9.21 (vs ₹7.49 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹1.52 (vs ₹1.72 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ₹3.03 (vs ₹1.80 in 2Q 2022)

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: ₹1.86 (vs ₹1.90 in 1Q 2022)

Par Drugs and Chemicals Limited, Annual General Meeting, Sep 10, 2022

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: ₹7.49 (vs ₹9.44 in FY 2021)

Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Non Executive Director recently bought ₹304k worth of stock

CEO & Executive Director recently bought ₹313k worth of stock

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

CEO & Executive Director recently bought ₹199k worth of stock

CEO & Executive Director recently bought ₹189k worth of stock

Investor sentiment deteriorated over the past week

Upcoming dividend of ₹1.25 per share

Second quarter 2022 earnings released: EPS ₹1.80 (vs ₹2.08 in 2Q 2021)

Investor sentiment deteriorated over the past week

Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Investor sentiment improved over the past week

Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Full year 2021 earnings released: EPS ₹9.44 (vs ₹3.87 in FY 2020)

Investor sentiment improved over the past week

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Investor sentiment improved over the past week

Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Investor sentiment improved over the past week

New 90-day high: ₹73.40

CEO & Executive Director recently bought ₹391k worth of stock

Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Chairman of the Board & MD recently bought ₹263k worth of stock

Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Investor sentiment improved over the past week

How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

Market bids up stock over the past week

New 90-day high: ₹55.90

New 90-day high: ₹51.00

New 90-day high: ₹50.45

New 90-day high - ₹50.00

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction